|
|
Post by jckrdu on Nov 4, 2014 21:30:23 GMT
Today makes the third day in row (so far) that ATHX has been making notable gains. Will it retrace and then restart without any visible news to drive it higher? All bets are off with any good news. Will it retrace? Yes... market answered that today.  I actually liked the trading today. Very nice volume. Traded higher the majority of the day, with a pullback in the last 30 minutes. Good consolidation over $1.50 IMO. |
|
|
|
Post by jckrdu on Nov 5, 2014 15:30:05 GMT
Today makes the third day in row (so far) that ATHX has been making notable gains. Will it retrace and then restart without any visible news to drive it higher? All bets are off with any good news. Will it retrace? Yes... market answered that today. I actually liked the trading today. Very nice volume. Traded higher the majority of the day, with a pullback in the last 30 minutes. Good consolidation over $1.50 IMO. Nice consolidation over $1.55 in the first hour this morning. Holding $1.55 was a good sign... 5-day chart looks good. Need to get some confirming news to help with the next leg up, although I'm more than happy to see additional consolidation anywhere in the $1.50s for a bit. |
|
|
|
Post by jckrdu on Nov 7, 2014 14:50:16 GMT
Nice consolidation over $1.55 continues. With the conference call on Monday after the close, hopefully we'll see a little more volume today.
|
|
|
|
Post by RLC on Nov 11, 2014 20:34:45 GMT
Just purchased another chunk at $1.48!
|
|
|
|
Post by jckrdu on Nov 11, 2014 21:25:07 GMT
Just purchased another chunk at $1.48! Averaging down from here is probably a good move RLC. Not sure when we'll see a beefy PR... worse case should be between Thanksgiving and X-Mass when they announce stroke enrollment completion. I'm hoping we don't have to wait that long for news as they have a lot going on. Hopefully the institutions will start to add some shares. I actually sold 10% of my shares today to build some cash and take a short-term position in STEM for their Nov 20th investor day event. Holding the rest of ATHX long.. or at least until March 2015 at which point I'll lighten up a bit prior to stroke results. |
|
|
|
Post by RLC on Nov 12, 2014 3:39:16 GMT
Congrats on the nice trade... Just opened up a little position in STEM myself.
|
|
|
|
Post by hophead on Nov 12, 2014 17:39:00 GMT
Sold for a small profit. Didn't want to be a bag holder. Seems as if most of the catalysts for this puppy are q1 next year? May re-enter at some point...
|
|
|
|
Post by jckrdu on Nov 12, 2014 18:41:55 GMT
Sold for a small profit. Didn't want to be a bag holder. Seems as if most of the catalysts for this puppy are q1 next year? May re-enter at some point... Possible. IMO, run-up will happen sooner. |
|
|
|
Post by JHam on Nov 13, 2014 1:53:45 GMT
Sold for a small profit. Didn't want to be a bag holder. Seems as if most of the catalysts for this puppy are q1 next year? May re-enter at some point... Well done! |
|
|
|
Post by jckrdu on Nov 13, 2014 12:54:13 GMT
Jason Kolbert, Maxim Group.Jason Kolbert, Maxim Group (11/10/14) "Athersys Inc.ended Q3/14 with $32M in cash, plenty of capital to fund the company through its next major catalyst, results of the Phase 2 stroke trial, where enrollment is almost complete. We are excited for results from its Phase 2 stroke trial. We are hopeful of good data (positive bias) and believe good data will be transformational to Athersys and the field."
|
|
|
|
Post by RLC on Nov 13, 2014 16:32:22 GMT
Wish I had more money to add at these prices! Can't see ATHX trading much lower than these prices (~$1.40/share) with so much on the horizon.
|
|
|
|
Post by jckrdu on Nov 13, 2014 17:02:20 GMT
Wish I had more money to add at these prices! Can't see ATHX trading much lower than these prices (~$1.40/share) with so much on the horizon. When they pushed stroke enrollment guidance completion from Oct/Nov to Nov/Dec, it took a little air out of the balloon. It'll start building again soon. 3 month chart still looks good. PR can come anyday out of nowehere for any one of the other programs besides stroke. |
|
|
|
Post by dayanand33 on Nov 15, 2014 14:33:58 GMT
This one is retracing back. Nice buying opportunity. In September an insider bought at 1.39. I am comfortable nibbling at anything less than that price.
|
|
|
|
Post by dayanand33 on Nov 15, 2014 21:45:14 GMT
Sadly the institutional holdings of ATHX reduced drastically to reduced to 11% www.nasdaq.com/symbol/athx/institutional-holdings/newThere was a big sell of in the 3rd quarter (almost 50% of the holdings) The good news started to trickle only in October. Hopefully they change their minds and start to buy. We need to keep a watch on this percentage in the 4th quarter. |
|
|
|
Post by jckrdu on Nov 25, 2014 18:25:56 GMT
Starting to creep back up.
Stroke enrollment completion guided to happen between Thanksgiving and X-Mass. Other news coming in December as well. Should see a 20%ish gain here to $1.75 to $1.80 IMO over the next 6 weeks.
|
|
|
|
Post by dayanand33 on Nov 25, 2014 21:47:35 GMT
Starting to creep back up. Stroke enrollment completion guided to happen between Thanksgiving and X-Mass. Other news coming in December as well. Should see a 20%ish gain here to $1.75 to $1.80 IMO over the next 6 weeks. You are forgetting the changes in the Japanese regulatory environment that are due before end of this year. If the company plays the PR card well, the pps could go much higher. |
|
|
|
Post by stemwinder on Nov 25, 2014 22:25:13 GMT
Starting to creep back up. Stroke enrollment completion guided to happen between Thanksgiving and X-Mass. Other news coming in December as well. Should see a 20%ish gain here to $1.75 to $1.80 IMO over the next 6 weeks. You are forgetting the changes in the Japanese regulatory environment that are due before end of this year. If the company plays the PR card well, the pps could go much higher. I can't see ATHX doing much. It may go up to $1.80, but not much more IMO. The CEO really blew his credibility earlier in the year by pumping the stock just before the failed UC data release. Many long term bulls got creamed and were very upset with him. Also, the 16 week data never got published to my knowledge, which is suspicious.
The stroke trial has some supporters on Yahoo concerned as they believe the efficacy endpoints are faulty and won't be hit.
|
|
|
|
Post by jckrdu on Nov 25, 2014 22:48:30 GMT
You are forgetting the changes in the Japanese regulatory environment that are due before end of this year. If the company plays the PR card well, the pps could go much higher. I can't see ATHX doing much. It may go up to $1.80, but not much more IMO. The CEO really blew his credibility earlier in the year by pumping the stock just before the failed UC data release. Many long term bulls got creamed and were very upset with him. Also, the 16 week data never got published to my knowledge, which is suspicious.
The stroke trial has some supporters on Yahoo concerned as they believe the efficacy endpoints are faulty and won't be hit.
UC (chronic disease) and stroke (sudden injury) are different animals. UC was treated with a single, low dose. Stroke trial is using much higher doses. In stroke, treatment is being given within 48 hours after the injury (the stroke)... versus UC which was a chronic disease some patients had for a decade. In summary, much better chance of efficacy in stroke versus UC. Also, clinicaltrials.gov was recently updated with new trial sites for UC, suggesting that UC is still moving forward in some manner with Pfizer. Primary stroke endpoints - and secondary endpoints - were just revised to address issue (that I agree with) with using only Rankin scores as the old primary endpoint. My bottomline with ATHX: Phase 2 will show some efficacy, and will be good enough to land a partner in Japan to start a pivotal trial in Japan with a big pharma partner, under the new Japanese conditional approval framework. |
|
|
|
Post by dayanand33 on Nov 26, 2014 15:21:45 GMT
Starting to creep back up. Stroke enrollment completion guided to happen between Thanksgiving and X-Mass. Other news coming in December as well. Should see a 20%ish gain here to $1.75 to $1.80 IMO over the next 6 weeks. You are forgetting the changes in the Japanese regulatory environment that are due before end of this year. If the company plays the PR card well, the pps could go much higher. As if on cue, the pump has begun seekingalpha.com/article/2713165-athersys-could-benefit-immensely-from-japan-reimbursement-on-stroke |
|
|
|
Post by jckrdu on Nov 26, 2014 16:11:23 GMT
Good article. Wall street titan writes good articles. Big implications for ATHX if stroke shows any efficacy. Per the CEO, plan is to land a partner to move forward in Japan. |
|
